Mainz Biomed BV (MYNZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mainz Biomed BV (MYNZ) has a cash flow conversion efficiency ratio of -6.957x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.46 Million) by net assets ($641.60K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Mainz Biomed BV (MYNZ) balance sheet quality index to measure how much of total assets are equity-financed.
Mainz Biomed BV - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Mainz Biomed BV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Mainz Biomed BV cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Mainz Biomed BV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mainz Biomed BV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Atlas Menkul Kiymetler Yatirim Ortakligi AS
IS:ATLAS
|
0.034x |
|
Redcastle Resources Ltd
AU:RC1
|
-0.103x |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
-0.039x |
|
Morella Corporation Ltd
AU:1MC
|
-0.082x |
|
ECOUP OYJ EO 1
F:62H
|
N/A |
|
Prima Globalindo Logistik Tbk
JK:PPGL
|
0.060x |
|
Electric Royalties Ltd
V:ELEC
|
-0.027x |
|
Solueta Co Ltd
KQ:154040
|
-0.026x |
Annual Cash Flow Conversion Efficiency for Mainz Biomed BV (2019–2025)
The table below shows the annual cash flow conversion efficiency of Mainz Biomed BV from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see MYNZ market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $641.60K | $-10.98 Million | -17.113x | -505.46% |
| 2024-12-31 | $6.05 Million | $-17.09 Million | -2.826x | +58.14% |
| 2023-12-31 | $3.25 Million | $-21.94 Million | -6.752x | -544.41% |
| 2022-12-31 | $14.10 Million | $-14.77 Million | -1.048x | -106.97% |
| 2021-12-31 | $6.36 Million | $-3.22 Million | -0.506x | -396.10% |
| 2020-12-31 | $-2.74 Million | $-468.74K | 0.171x | -19.94% |
| 2019-12-31 | $-1.95 Million | $-416.50K | 0.214x | -- |
About Mainz Biomed BV
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes … Read more